Update on the assessment of resistance to antidepressant treatment: Rationale for the Antidepressant Treatment History Form: Short Form-2 (ATHF-SF2)

J Psychiatr Res. 2024 Aug:176:325-337. doi: 10.1016/j.jpsychires.2024.05.046. Epub 2024 Jun 12.

Abstract

All definitions of treatment-resistant depression (TRD) require that patients have experienced insufficient benefit from one or more adequate antidepressant trials. Thus, identifying "failed, adequate trials" is key to the assessment of TRD. The Antidepressant Treatment History Form (ATHF) was one of the first and most widely used instruments that provided objective criteria in making these assessments. The original ATHF was updated in 2018 to the ATHF-SF, changing to a checklist format for scoring, and including specific pharmacotherapy, brain stimulation, and psychotherapy interventions as potentially adequate antidepressant treatments. The ATHF-SF2, presented here, is based on the consensus of the ATHF workgroup about the novel interventions introduced since the last revision and which should/should not be considered effective treatments for major depressive episodes. This document describes the rationale for these choices and, for each intervention, the minimal criteria for determining the adequacy of treatment administration. The Supplementary Material that accompanies this article provide the Scoring Checklist, Data Collection Forms (current episode and composite of previous episodes), and Instruction Manual for the ATHF-SF2.

Keywords: Antidepressant treatment resistance; Brain stimulation; Major depressive episode; Pharmacotherapy; Psychotherapy; Treatment-resistant depression.

Publication types

  • Review

MeSH terms

  • Antidepressive Agents* / pharmacology
  • Antidepressive Agents* / therapeutic use
  • Depressive Disorder, Major / drug therapy
  • Depressive Disorder, Major / therapy
  • Depressive Disorder, Treatment-Resistant* / drug therapy
  • Depressive Disorder, Treatment-Resistant* / therapy
  • Humans
  • Outcome Assessment, Health Care

Substances

  • Antidepressive Agents